Integrated Commercial and Government Applications Will Improve Speed and Accuracy of Revenue Management Processes SOUTH SAN FRANCISCO, Calif., June 22 /PRNewswire/ -- Model N, Inc., the pioneer in revenue management solutions for life sciences, announced that Axcan Pharma Inc., a leading specialty pharmaceutical company specialized in the field of gastroenterology, has selected Model N Revenue Management for both commercial and government applications. Axcan Pharma will be implementing Model N Contract Management and Chargebacks, as well as, Government Pricing and Medicaid Claims Processing applications. Model N Revenue Management is the first suite of applications to align and integrate the pricing, contract management, settlements and government compliance processes for pharmaceutical manufacturers. "Our clear focus on one therapeutic area -- gastroenterology -- is one of the principals that has enabled Axcan Pharma to build its reputation, and to better serve patients and specialized caregivers," said Kent Pickering, Senior Director of Managed Care for Axcan Pharma. "We apply that same focus to pursuing excellence in our operations, and with our selection of Model N we believe we have a technology platform that will help us continue to improve efficiency in commercial contracting and enhance our overall regulatory compliance efforts." The Model N Revenue Management Suite is based on a common platform built from the ground up to meet the changing realities facing life sciences companies today. The suite includes an end-to-end integrated set of applications that address the specific pricing, reimbursement and compliance challenges involved in managing revenue from both commercial and government contracts. Each of the applications in the suite share common data, workflow, business analysis, and access to common membership, contracts and pricing programs. The applications are "self-aware" and automatically recognize and act on changes made in another application. In addition, Model N Revenue Management provides integrated price monitoring of commercial and government pricing thresholds, highlighting the impact on any changes in both directions -- another one of the first in the industry advances of Model N Revenue Management. This suite of applications allows companies to benefit from a single platform approach, rather than investing in multiple applications that do not integrate and that create gaps in the revenue management business process that lead to regulatory compliance exposure and revenue leakage. "The selection of Model N Revenue Management applications by Axcan Pharma is a significant honor for the company, and evidence that a growing number of forward thinking pharmaceutical manufacturers are beginning to invest in technology to align both their commercial and government operations," said Zack Rinat, founder and CEO of Model N. "By working with innovative companies who are focused on improving their ability to serve their customers, like Axcan Pharma, we have developed a suite of integrated applications that are unique in their ability to manage the entire revenue life cycle -- from pricing through reimbursements. We look forward to working with Axcan through the implementation and over time, as a Model N customer, to continue to advance our solutions to meet the emerging needs of the industry." About Axcan Pharma Axcan is a leading specialty pharmaceutical company involved in the field of gastroenterology. The Company markets a broad line of prescription products sold for the treatment of symptoms in a number of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to cystic fibrosis. Axcan's products are marketed by its own sales force in North America and Europe. Its common shares are listed on the Toronto Stock Exchange under the symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA". About Model N Model N is the pioneer in Revenue Management solutions, offering an integrated suite of applications for pricing, contracts, compliance, rebates, fees and chargebacks optimized for the industry practices of life sciences companies. Enabling the creation of a seamless, end-to-end process from pricing through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government pricing and Sarbanes-Oxley regulations. Model N customers include Actelion Biopharmaceuticals; Axcan Pharma Inc., Boston Scientific Corporation; Bristol-Myers Squibb; Gilead Sciences; Ortho-Clinical Diagnostics, a Johnson & Johnson company; Pfizer, Inc.; Medtronic, Inc.; and Reliant Pharmaceuticals, Inc. Model N is located in South San Francisco, California. For additional information, visit http://www.modeln.com/. NOTE: Model N is a mark of Model N, Inc. All other company names mentioned are the property of their respective owners and are mentioned for identification purposes only. DATASOURCE: Model N, Inc. CONTACT: media, Carey Godbee of B3 Communications, +1-760-758-4406, or , for Model N; or Isabelle Adjahi, Director, Investor Relations, of Axcan Pharma Inc., +1-450-467-2600, ext. 2000 Web site: http://www.axcan.com/ Web site: http://www.modeln.com/

Copyright